A-05 Novel Therapeutic Strategy for B Cell Malignant Lymphocyte
- Technology Benefits
- ΓùÅ CD20 negatively converted B cell malignant lymphocyte cell line is availableΓùÅ An animal model indicating the pathological conditions of CD20-negatively converted B cell malignant lymphocyte is availableΓùÅ A method is available for screening a substance which is efficacious against CD20 positive B cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte.
- Technology Application
- ΓùÅ Treatment for rituximab resistant B cell malignant lymphocyteΓùÅ Screening agent for rituximab resistant B cell malignant lymphocyte
- Detailed Technology Description
- A) RRBL1 is CD20 negative, resistant to rituximab B cell malignant lymphocyte. Isolated rituximab resistant B cell malignant lymphocyte. This cell line shows rituximab resistance in vitro and feasible to be transplanted into an immunodeficient mouse.B) Induction of CD20 expression by RRBL1 treatment. CD20-negative conversion phenomena after treatment with rituximab is detected in ┬╝ of recurrence. Treating this cell line by various drugs, an effective condition was verified which would induce CD20 expression. This condition will induce protein expression of CD20 on the cell surface.
- Supplementary Information
- Patent Number: HK1054628A1
Application Number: HK2003106837A
Inventor: LIU CHIU-PONG JOE | POON NGAI-KIT FRANKI | PONG MAN-HAY BRYAN
Priority Date: 24 Aug 2001
Priority Number: HK1054628A1
Application Date: 23 Sep 2003
Publication Date: 23 Dec 2005
IPC Current: B29C004576 | G06F000130 | H02M000112
Assignee Applicant: The University of Hong Kong
Title: Apparatus for noise current reduction in power converters.
Usefulness: Apparatus for noise current reduction in power converters.
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- *Abstract
-
Nagoya University is seeking companies interested in commercializing a novel therapeutic strategy for B cell malignant lymphocyte resistant to rituximab. Researchers at Nagoya University have isolated a B cell lymphocyte clone that was negatively inverted after treatment with rituximab (anti-CD20monoclonalantibody). This cell line is a useful tool for developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug.
- Country/Region
- USA
For more information, please click Here
